Clinical Trial

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 23, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous system lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-01-30; most recent amendment 2025-04-18.
Trial Details
NCT Number NCT04737889
Lead Sponsor Henan Cancer Hospital
Conditions Primary Central Nervous System Lymphoma
Enrollment 30 participants
Start Date 2021-01-13
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-01-13 (estimated)
Updated on ClinicalTrials.gov 2025-04-23